GLP-1 receptor agonists produced 7.5% total body weight loss at 12 months among Chinese patients who experienced suboptimal results after bariatric surgery, compared to just 1.2% with standard care alone. The 6.28 percentage point difference emerged from a rigorous target trial emulation involving 624 patients across two tertiary hospitals, with 75% of GLP-1 RA patients achieving clinically meaningful ≥5% weight loss versus only 7% in standard care. This represents a paradigm shift for post-bariatric care. The one-in-four patients who don't achieve adequate weight loss after sleeve gastrectomy or gastric bypass have historically faced limited options beyond revision surgery. These findings suggest pharmacotherapy can salvage disappointing surgical outcomes, potentially transforming the treatment algorithm for the substantial minority of bariatric surgery patients who plateau early. The real-world evidence from China's healthcare system adds crucial generalizability beyond small Western trials. However, the observational design, despite sophisticated propensity matching, cannot establish causation. The integration of GLP-1 agonists into post-surgical protocols could optimize the substantial investment patients make in bariatric procedures, offering hope for those facing surgical disappointment.